Table 3.
One-year follow-up univariate and multivariate survival analysis in FIGO stage III-IV for FOLR1 mRNA expression
| Univariatea | Multivariateb | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS | OS | PFS | OS | |||||||||||||
| Months (median) | CI 95 % | HR | p value | Months (median) | CI 95 % | HR | p value | HR | CI 95 % | p value | HR | CI 95 % | p value | |||
| Type I | FOLR1 mRNA expressionc | Weak | 8.56 | 7.06-10.06 | 0.246 [0.081-0.743] | 0.006** | 10.25 | 9.06-11.44 | 0.093 [0.012-0.717] | 0.004** | 0.38 | 0.16-0.87 | 0.023* | 0.59 | 0.007-0.52 | 0.011* |
| Strong | 11.25 | 10.08-12.41 | 11.64 | 10.95-12.33 | ||||||||||||
| Grading | G1 VS G2-3 | 0.62 | 0.35-1.65 | 0.416 | 1.11 | 0.29-4.18 | 0.880 | |||||||||
| Age | < o > median | 0.76 | 0.36-1.58 | 0.461 | 1.46 | 0.69-3.05 | 0.317 | |||||||||
| Residual disease | 0 VS >0 | 2.04 | 0.71-5.83 | 0.183 | 1.33 | 0.37-4.29 | 0.661 | |||||||||
| histologyd | 1.73 | 0.94-3.37 | 0.077 | 2.01 | 0.94-4.29 | 0.071 | ||||||||||
| FIGO stage | I-II VS III-IV | 2.08 | 0.84-5.11 | 0.110 | 1.01 | 0.30-3.83 | 0.982 | |||||||||
| Type II | FOLR1 mRNA expressionc | Weak | 9.17 | 7.94-10.40 | 0.904 [0.577-1.414] | 0.183 | 11.25 | 10.38-12.12 | 0.586 [0.170-2.023] | 0.390 | ||||||
| Strong | 10.30 | 9.57-11.02 | 11.68 | 11.30-12.05 | ||||||||||||
Cut off for FOLR1 mRNA expression = median value in the cancer cohort (9.14) *Significant at the 0.05 level, **Significant at the 0.01 level alog rank test, bCOX-regression analysis;
cArbitrary units normalized to TBP. dSerous, endometrioid, mucinous and clear cell. Multivariate analysis was performed if p-value in univariate analysis was > 0.1